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Background: Breast cancer is the most common malignancy and the second leading cause of death in women.
Because bone metastases are a common finding in patients with breast cancer, they are of major clinical concern.
Methods: In 115 consecutive patients with bone metastases secondary to breast cancer, 132 surgical procedures
were performed. Medical records and imaging procedures were reviewed for age, treatment of the primary tumor,
clinical symptoms, surgical treatment, complications, and survival.
Results: The overall survival of patients with metastatic breast cancer was dependent on the site and the amount
of the metastases. Age was not a prognostic factor for survival. If the result of the orthopaedic surgery was a wide
resection (R0) survival was significantly better than in the R1 (marginal resection – tumor resection in sane tissue)
or R2 (intralesional resection) situation. Concerning the orthopaedic procedures there was no survival difference.
Conclusion: In conclusion a wide (R0) resection and the absence of pathological fracture and visceral metastases
were predictive for longer survival in univariate analysis. Age and the type of orthopaedic surgery had no impact
on survival in multivariate analysis. The resection margins lost significance. The standard of care for patients with
metastatic breast cancer to the bone requires a multidisciplinary approach.
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Breast cancer is the most common malignancy and the
second leading cause of death in women. It was esti-
mated that approx. 180.000 women were newly diag-
nosed with breast cancer in the USA in 2008 and about
40.000 died of that disease [1]. The lifetime risk of devel-
oping invasive breast cancer in the USA is 12.6% (one
out of eight women [2]. In autopsy studies, metastases in
the skeleton occur at least as frequently as those in the
lung [3]. It is well recognized that there is a relatively in-
dolent course of the disease in many patients with pre-
dominantly bone metastases [4], while other patients
suffer from severe pain [5]. Because bone metastases are
a common finding in patients with breast cancer, they
are of major clinical concern. In a population based
study Wedin et al. found that of the breast cancer* Correspondence: Hans_Roland.Duerr@med.uni-muenchen.de
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reproduction in any medium, provided the orpatients who presented with symptomatic skeletal me-
tastases 17% needed surgery [6]. Pathologic fractures
represent severe complications in these patients, espe-
cially fractures of the spinal vertebrae with spinal cord
compression. The mean survival time of patients with
bone metastases varies between 24 and 34 months [7,8].
With new systemic therapeutics available the survival
time will increase and orthopaedic surgeons will see
more breast cancer patients with bone metastases.
Different therapeutic options are available for treating
symptomatic bone metastases, such as analgesics and
systemic chemotherapy for pain relief as well as radio-
therapy and prophylactic stabilisation for long term pre-
vention of fractures [9]. In case of a pathological fracture
surgery is inevitable in most cases. Patient selection is
an important criterion regarding survival benefits and
quality of life after surgical intervention. To evaluate
prognostic factors on survival, a consecutive series of
115 patients with breast cancer, who were surgically
treated for bone metastases in our institution, wereal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Location of 132 surgical procedures.
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treatment results were analyzed.
Methods
Between January 1980 and September 2005, in 115 con-
secutive patients (112 women, 3 men) with bone metas-
tases secondary to breast cancer 132 surgical procedures
were performed. Medical records and imaging proce-
dures were reviewed for age, treatment of the primary
tumor, clinical symptoms, surgical treatment, complica-
tions, and survival. Statistical analyses were performed
using the Cox regression for multivariate analysis,
Kaplan-Meier life table analyses, and log-rank test for
univariate analysis. The study was approved by the eth-
ical committee.
Results
The mean age of the 115 patients at the time of oper-
ation was 57.3 years (range: 30.6–83.6 years). Systemic
hormone treatment was administered to 18 patients
(16%), chemotherapy to 41 patients (36%), and radiation
therapy to 61 patients (53%); some patients received a
combination of the three therapies.
Nearly all patients presented with pain (98%); 72
patients (63%) had a pathologic fracture, fourteen patients
(12%) had neurological impairments due to spinal com-
pression. The mean duration of symptoms was 4.5 months
(median: 2.9 months; range: 0–56 months). In 13 (11%)
patients, breast cancer was diagnosed as a result of symp-
toms caused by osseous metastases. At presentation
9 (8%) patients had a solitary osseous lesion, 57 (49.5%)
patients had more than one lesion, and 49 (42.5%)
patients had an additional visceral involvement. The time
from diagnosis of breast cancer to bone metastases sur-
gery ranged from 0 to 30 years (mean: 5.7 years median:
4.3 years). Eighteen percent of the patients needed surgi-
cal therapy for bone metastases in the first year, 58% in
the first 5 years, and 89% in the first 10 years. Fourteen
patients (12%) had an interval longer than 10 years, nine
of these were the ones who showed solitary bone matas-
tases and were treated with wide resections.
The locations of the surgical procedures are shown in
Figure 1. The most common locations of bone metasta-
ses were the spine (65 patients) and the proximal femur
(46 patients). (humerus: 8, pelvis: 5 and ribs: 5, others: 3)
Indications for treatment were untreatable pain, in-
stability, impending fractures or fractures of the long
bones and spinal compression because of tumor. Surgi-
cal therapy in the 115 patients varied depending on the
site of the tumor, the extent of disease and the patient’s
general health status.
Incisional biopsy was done in 14 (12%) patients. In
one patient resection of the proximal humerus without
reconstruction was done.In 65 patients with involvement of the spine, 5 were
treated with vertebroplasty and 4 with dorsal decom-
pression only. In 32 patients dorsal instrumentation was
used and in 17 patients a partial or complete vertebral
resection with ventral stabilisation was done. In 7
patients only a CT-guided biopsy was taken for confirm-
ation of diagnosis.
In 15 patients resection of the tumor and implantation
of a tumor-endoprosthesis was performed, including one
patient with an acetabular resection and reconstruction
with a custom-made endoprosthesis. 19 patients received
a standard hip arthroplasty, and one patient received a
semiconstrained knee endoprosthesis. In 9 patients with
solitary bone lesions without visceral tumor spread, a
wide tumor resection was done. In 60 patients, as the
intention was palliation, the surgical procedure was
intralesional or marginal.
Figure 3 Survival and location of metastases: 0 = solitary bone
metastase, 1 =multiple bone metastases, 2 = visceral
metastases.
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associated with the surgical procedures. Among these
complications deep venous thrombosis (n = 3), in one
case with a severe embolic event, postoperative haema-
toma (n = 3) and failure of osteosynthesis (n = 3) were
the most common. Furthermore we saw two wound
healing complications, one non-union, one deep infec-
tion, one multi organ failure and in one case a persistent
neurological deficit. Six patients died within the first
30 days after surgery. The median overall survival in our
cohort was 17 months after diagnosis of bone
metastases.
The overall survival of patients with metastatic breast
cancer was dependent on the site and the amount of the
metastases. Whereas patients with a solitary bone lesion
had the best survival with a medium of 65 months,
patients with visceral metastases had a medium survival
of 13 months (Figure 2, Figure 3) after diagnosis of bone
metastases.
Age is not a prognostic factor of survival, as in the
group of patients < 55 years or > 55 years no statistical
difference could be shown. On the other hand patients
with fracture of an extremity had an adverse median sur-
vival (10 months) in comparison to patients without
fracture (25 months, Figure 4), which showed a statis-
tical significance (p = 0.0001).
If the result of the orthopaedic surgery was a wide re-
section (R0) survival was significantly (p = 0.0123) better
than in the R1 or R2 situation (not reached vs 19 months
vs 12 months, Figure 5).
Concerning the orthopaedic procedures there was no
survival difference whether nail, SSTP (standard tumor
prosthesis) or TTEP (tumor total endoprosthesis) was
done (p = 0.1695).
In a multivariate approach to overall survival (Table 1)
the margins and the fractures lost significance. Patients
over 55 years showed now a slightly decreased prognosis,Figure 2 Overall survival.the dissemination of the disease proved to be the most
important and highly significant influencing factor of
overall survival.
Discussion
We analyzed retrospectively 115 patients in the Univer-
sity Hospital of Munich, Germany who underwent 132
orthopedic surgery procedures because of metastatic
breast cancer to evaluate prognostic factors of survival.
Our cohort is heterogeneous as patients with limited
disease or just one bone lesion and patients in the end
stage of their disease with multiple lesions or fractures
were analyzed. The time after first diagnosis of breast
cancer until the diagnosis of bone metastases was me-
dian 4.3 years (0–30 years), which is in concordance
with other cohorts [6].Figure 4 Survival and fracture, 1 = fracture, 0 = no fracture.
Figure 5 Survival and R-status 0 = R0, 1 = R1, 2 = R2.
Wegener et al. BMC Musculoskeletal Disorders 2012, 13:232 Page 4 of 5
http://www.biomedcentral.com/1471-2474/13/232Patients with metastatic breast cancer are in need of a
systemic therapeutic approach as metastatic breast can-
cer is a systemic disease. Patients with absence of vis-
ceral metastases had an improved survival in contrast to
patients with e.g. liver metastases. The combination of
an antihormonal therapy, therapy with monoclonal anti-
bodies in her-2 positive disease, cytotoxic agents and
tyrosinkinase-inhibition may delay disease progression in
these patients. Therefore the treatment of bone metasta-
ses, besides systemic treatment, includes different
aspects as analgetics, bisphosphonates, radiation therapy
and surgery [10]. Bisphosphonates are standard of care
in prevention and treatment of osteolytic and osteo-
blastic bone metastases increasing the time to skeletal
complications in patients with breast cancer [11-13].
Radiation therapy diminishes pain in most patients
during ongoing treatment [14]. For patients without
clinical benefit during radiation orthopedic surgery may
be beneficial. An assessment of risk for pathological
fractures should be implemented to perform prophy-
lactic surgery [15]. Here a non-invasive CT (computed
tomography)-based diagnosis can help oncologists and
orthopaedic surgeons to predict fractures caused by
breast cancer metastases [16].Table 1 Multivariate analysis of overall survival in
dependence to tumor dissemination (solitary bone,
multiple bone, visceral), fracture (yes/no), Age
(<=55 y/>55 y) and margins (R0, R1, R2)
Covariate SE P 95% Cl of Exp(b)
Tumor 0,2562 <0,0001 2,3939 to 6,5032
Dissemination
Fracture 0,2576 0,5238 0,7131 to 1,9474
Age 0,01229 0,0116 1,0071 to 1,0565
Margin 0,2216 0,9564 0,6413 to 1,5219The role of surgery in the palliative setting is to con-
trol pain or neurologic symptoms, stabilize fractures, im-
prove function and remobilize patients. The location of
the lesion or the complication guide surgical procedures.
Large humeral or femoral segments can be recon-
structed with endoprosthesis of new prosthetic materials
[17,18]. We performed more endoprosthesis (27%) than
osteosynthesis (17%), as these are beneficial for selected
patients with metastatic tumors and bone loss, what we
and others have shown before [19-22]. A wide resection
(R0) could, on the first sight, significantly improve sur-
vival (p = 0.0123) in comparison to R1 or R2 resection.
The median survival was not reached for the R0 group,
in contrast to a median survival of 19 months in the R1
and 12 months for the R2 group. But those patients had
a more limited disease and had been in a better general
condition. They hence had been treated more aggres-
sively. So we think this survival benefit is based on a se-
lection bias. This is also proved by the multivariate
analysis shown in Table 1.
Affection of the vertebra can be stabilized by “internal
bracing” or screws in selected cases, allowing decom-
pression of neural structures. As these procedures often
do not lead to complete excision of the tumor lesion,
delayed anterior approaches in combination with sys-
temic therapy may be performed [23]. Attempts of local
radical excision are meaningless in systemic metastatic
breast cancer [24]. In an analysis of 125 surgical inter-
ventions in 87 breast cancer patients the surgical proce-
dures to the spine provided pain relief and preservation
or improvement of the neurological function [25].
Kyphoplasties showed to be a feasible option in 555
patients with 1150 vertebral fractures [26].
Pathologic fractures are strong indications for surgical
procedures. The high percentage of patients with patho-
logic fractures (49%) in our series reflects, that our co-
hort had a poor prognosis. According to Bauer et al. we
also found that a fracture of an extremity was a negative
prognostic factor [27]. This could not be demonstrated
for spinal fractures. The median survival for patients
without fractures in comparison to patients with frac-
tures was significantly longer (25 months vs. 10 months),
which should encourage to perform orthopedic surgery
in an earlier stage of disease to prevent fractures. The
method of surgery (nail, SSTP or TTEP) had no influ-
ence on survival in our patients. The complication rate
of 11% in our institution is low and in the range of other
published series [25]. 9 patients with solitary bone me-
tastases had been in the group of long survivors. We be-
lieve this is a bias. These patients had a more limited
disease and had been in a better general condition and
hence have been treated more aggressively.
A limitation of our study is caused by the long follow
up period. Systemic and radiological therapies and
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tiation of these parameters is not possible.
Conclusions
In conclusion the possibility of a wide (R0) resection and
the absence of pathological fractures and visceral metasta-
ses were predictive for longer survival, whereas age and
the type of orthopaedic surgery had no impact on survival.
Due to new treatment modalities patients with meta-
static breast cancer live longer, which alters the failure
possibility of a surgical reconstruction. In these patients
wide resection as performed in primary bone tumors,
should be considered. This might encourage to use
endoprosthetic rather than osteosynthetic techniques.
The standard of care for patients with metastatic
breast cancer to the bone requires a multidisciplinary
approach including radiotherapy, surgery and systemic
treatment. Orthopedic surgeons should be active mem-
bers in this multidisciplinary team with oncologists, radi-
ologists and radiation-oncologists. Their part will
become more important in the future as new operative
techniques and materials will enable patients with meta-
static breast cancer, who live longer because of better
systemic approaches, to live with a better quality of life.
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